Onset of Effect of 5-HT1B/1D Agonists: A Model with Pharmacokinetic Validation

Headache

Volumn 44, Issue 2, 2004, Pages 142-147

  Fox, Anthony W ^a  

^a EBD Group   (United States)

Author keywords

5 H1B 1D agonists; Absorption; Efficacy; Migraine

Indexed keywords

SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN;

ARTICLE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; MIGRAINE; MODEL; NEUROPHARMACOLOGY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; VALIDATION PROCESS;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIGRAINE DISORDERS; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS;

EID: 1242321180     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04030.x     Document Type: Article

References (19)

1. Dodick DW, Silberstein S, Dahlöf CG. Is there a preferred triptan? Headache. 2002;42:1-7.
2. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what migraine patients want from therapy? Headache. 1999;39(suppl 2):S20-S26.
3. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000;20:554-560.
4. Göbel H, Petersen-Braun M, Heinze A. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. New York: Lippincott-Raven; 1997;6:93-97.
5. 1B/1D agonists. Headache. 2001;41:257-263.
6. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H, for the US Sumatriptan Research Group. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
7. Laska EM, Siegel C. Assessing the onset of relief of a treatment for migraine. Cephalalgia. 2000;20:724-731.
8. Géraud G. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Cephalalgia. 2001;21:406-407.
9. Tepper SJ, Cochran A, Hobbs S, Woessner M, and the S2B-351 Study Group. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract. 1998;51:31-35.
10. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal, and intranasal administration. Eur J Pharm Sci. 1998;6:99-104.
11. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner R, Baber N. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
12. 1B/1D agonist efficacy in migraine. Headache. 2002;42:680-688.
13. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457-478.
14. Fox AW. Onset of effect of acute migraine therapies: logarithmic model comparison among varied pharmacological classes [abstract]. Headache. 2003;43:520.
15. Stephenson RP. A modification of drug-receptor theory. Br J Pharmacol. 1956;11:379-393.
16. 1 adrenoceptors and contraction of rat vas deferens. Mol Pharmacol. 1983;23:359-363.
17. Paton WD. A theory of drug action based upon the rate of drug-receptor combination. Proc R Soc Lond B Biol Sci. 1961;154:21-69.
18. 1B/1D agonists: exploration for a parameter of rate, not extent [abstract]. Cephalalgia. 2001;21:443-444.
19. Fox AW. Comparison of two models for rate (rather than extent) of population response to acute migraine therapies [abstract]. Headache. 2002;42:409.